Gilliland Jeter Wealth Management LLC Buys 88 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Gilliland Jeter Wealth Management LLC boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,039 shares of the medical equipment provider’s stock after purchasing an additional 88 shares during the period. Gilliland Jeter Wealth Management LLC’s holdings in Intuitive Surgical were worth $2,476,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the second quarter valued at about $26,000. Godsey & Gibb Inc. boosted its position in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. Creekmur Asset Management LLC grew its stake in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. LGT Financial Advisors LLC grew its position in Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 54 shares during the last quarter. Finally, Delos Wealth Advisors LLC increased its position in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ISRG shares. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Evercore ISI reiterated a “cautious” rating on shares of Intuitive Surgical in a research note on Friday. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a report on Friday. BTIG Research set a $535.00 target price on shares of Intuitive Surgical in a research note on Friday. Finally, Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Stock Up 10.0 %

NASDAQ:ISRG opened at $521.15 on Monday. The business’s 50-day simple moving average is $483.85 and its two-hundred day simple moving average is $438.56. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $523.34. The stock has a market cap of $184.85 billion, a PE ratio of 94.07, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the company earned $1.18 EPS. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 over the last quarter. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.